QNRX

Quoin Pharmaceuticals Ltd DRC

QNRX, USA

Quoin Pharmaceuticals, Ltd., a late stage specialty pharmaceutical company, focuses on the development and commercialization of therapeutic products for rare and orphan diseases in the United States. The company's lead product is QRX003, a topical lotion to treat Netherton Syndrome (NS). It also developing QRX004 for the treatment of recessive dystrophic epidermolysis bullosa; QRX007 to treat Netherton Syndrome; and QRX008 for the treatment of scleroderma. It has a research agreement with Queensland University of Technology; a license agreement with Skinvisible Inc.; consulting agreements with Axella Research LLC; and a Master Service Agreement with Therapeutics Inc. Quoin Pharmaceuticals, Ltd. was founded in 2018 and is based in Ashburn, Virginia. Quoin Pharmaceuticals, Ltd. is a subsidiary of Skinvisible, Inc.

https://quoinpharma.com

Stock Price

$0.00

0%

decrease compared to yesterday.

Dividend

Frequency:

N/A

Rate:

N/A

Next Payout:

N/A
QNRX
stock
QNRX

Saudi move could bring first-ever Netherton treatment to patients in 2026 Stock Titan

Read more →
QNRX
stock
QNRX

Quoin Pharmaceuticals Files for Breakthrough Designation for QRX003, Potential First Treatment for Netherton Syndrome Intellectia AI

Read more →

Showing 2 of 10

Analyst Ratings & Sentiment

(Last Updated 2025-09-30)

Rating:

STRONG BUY

Target Price:

$40.6667

Analyst Picks

Strong Buy

1

Buy

1

Hold

0

Sell

0

Strong Sell

0

Finn Analysis

(Last Updated 2025-09-30)

Health Score

Price to Book Ratio (P/B)

-

Very Low

-5.28

Low ≤ 1

High ≥ 3

Return on Equity (ROE)

-

Very High

325.05 %

Low ≤ 5%

High ≥ 25%

Return on Assets (ROA)

-

Very Low

-61.46 %

Low ≤ 2%

High ≥ 10%

Investors

* Institutions hold a combined 0.31% of the total shares of Quoin Pharmaceuticals Ltd DRC

1.

Rhumbline Advisers

(0.2112%)

since

2025/06/30

2.

GAMMA Investing LLC

(0.0408%)

since

2025/06/30

3.

Morgan Stanley - Brokerage Accounts

(0.035%)

since

2025/06/30

4.

UBS Group AG

(0.0221%)

since

2025/06/30

5.

Fidelity Nasdaq Composite Index

(0.0024%)

since

2024/04/30

6.

SBI Securities Co Ltd

(0.0003%)

since

2025/06/30

7.

Altium Capital Management, LP

(0%)

since

2025/03/31

8.

Ikarian Capital, LLC

(0%)

since

2025/03/31

9.

Renaissance Technologies Corp

(0%)

since

2025/03/31

10.

Armistice Capital, LLC

(0%)

since

2025/03/31

11.

XTX Topco Ltd

(0%)

since

2025/03/31

12.

TWO SIGMA SECURITIES, LLC

(0%)

since

2025/03/31

13.

BOOTHBAY FUND MANAGEMENT, LLC

(0%)

since

2025/03/31

14.

HRT FINANCIAL LLC

(0%)

since

2025/03/31

* Investors data is estimated based on stocks listed on Finnton that are currently held by Institution/Fund.

Earnings History

EPS ActualEPS EstimateEPS DifferenceSurprise Percent

Upcoming Earnings Release

Date

—

EPS Estimate

—

Latest Release

Date

2025-09-30

EPS Actual

-6.72

EPS Estimate

-0.6

EPS Difference

-6.12

Surprise Percent

-1020%

Investing Fit Scorecard

(Last Updated 2025-09-30)

Deep Value
Weak Deep Value(1)
Defensive
Highly Defensive(7)
Dividend
Weak Dividend Profile(1.5)
Economic Moat
Some Competitive Advantage(5.3)
GARP
Not Attractive for GARP(2)
Growth
Weak Growth Prospect(2)
Momentum
No Momentum(2)
Net Net
Not Undervalued (Net-Net)(0.5)
Quality
Low Quality Business(2.5)
Value
Fair Value(4)

Income Statement

(Last Updated 2025-09-30)

Revenue

$ 0

Cost Of Revenue

$ 0

Gross Profit

$ 0

Operating Expenses

$ 0

Operating Income

$ 0

Interest Expense

$ 0

Pretax Income

$ 0

Net Income

$ 0

Income Tax Expense

$ 0

EBITDA

$ 0

Total Other Income Expense Net

$ 0

Earnings Per Share

0

Dividends Per Share

0

Shares Outstanding

0

Operating Margin

0%

Trend

Balance Sheet

(Last Updated 2025-09-30)

Cash

$ 0

Short Term Investments

$ 0

Receivables

$ 0

Inventories

$ 0

Total Current Assets

$ 0

Property Plant Equipment

$ 0

Total Assets

$ 0

Payables

$ 0

Short Term Debt

$ 0

Long Term Debt

$ 0

Total Liabilities

$ 0

Equity

$ 0

Trend

Cash Flow

(Last Updated 2025-09-30)

Net Income

$ 0

Depreciation

$ 0

Change In Working Capital

$ 0

Cash From Operations

$ 0

Capital Expenditures

$ 0

Cash From Investing

$ 0

Cash From Financing

$ 0

Net Change In Cash

$ 0

Trend

Disclaimer: Finnton is a stock screener tool provided for informational and educational purposes only. The data, analysis, and insights offered on this website do not constitute financial, investment, tax, or legal advice. Users are solely responsible for their own investment decisions, and Finnton makes no guarantees regarding the accuracy, completeness, or reliability of the information provided. Past performance is not indicative of future results. Always conduct your own research and consult with a licensed financial advisor before making any investment decisions.